- Home
- ITRM vs DMAC Comparison
ITRM vs DMAC Comparison
Compare ITRM & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- DMAC
- Stock Information
- Founded
- ITRM 2015
- DMAC 2000
- Country
- ITRM Ireland
- DMAC United States
- Employees
- ITRM N/A
- DMAC N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- DMAC Health Care
- Exchange
- ITRM Nasdaq
- DMAC Nasdaq
- Market Cap
- ITRM 37.7M
- DMAC N/A
- IPO Year
- ITRM 2018
- DMAC N/A
- Fundamental
- Price
- ITRM $1.23
- DMAC $4.18
- Analyst Decision
- ITRM Strong Buy
- DMAC Strong Buy
- Analyst Count
- ITRM 1
- DMAC 3
- Target Price
- ITRM $5.00
- DMAC $8.00
- AVG Volume (30 Days)
- ITRM 382.6K
- DMAC 90.3K
- Earning Date
- ITRM 05-12-2025
- DMAC 05-07-2025
- Dividend Yield
- ITRM N/A
- DMAC N/A
- EPS Growth
- ITRM N/A
- DMAC N/A
- EPS
- ITRM N/A
- DMAC N/A
- Revenue
- ITRM N/A
- DMAC N/A
- Revenue This Year
- ITRM N/A
- DMAC N/A
- Revenue Next Year
- ITRM $150.10
- DMAC N/A
- P/E Ratio
- ITRM N/A
- DMAC N/A
- Revenue Growth
- ITRM N/A
- DMAC N/A
- 52 Week Low
- ITRM $0.81
- DMAC $2.14
- 52 Week High
- ITRM $3.02
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ITRM 52.71
- DMAC 51.60
- Support Level
- ITRM $1.01
- DMAC $3.34
- Resistance Level
- ITRM $1.42
- DMAC $3.88
- Average True Range (ATR)
- ITRM 0.09
- DMAC 0.30
- MACD
- ITRM 0.03
- DMAC 0.14
- Stochastic Oscillator
- ITRM 60.98
- DMAC 97.51
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.